Document is current
Any future updates will be listed below
-
Authors
Ziegler, Andreas Kraag https://orcid.org/0000-0001-7024-8536
Christensen, Mette
Jørgensen, Henrik Løvendahl
Fenger, Mogens
Myrup, Sara Fogh
Dirksen, Carsten
Madsbad, Sten
- License Information
-
More Information
Article History
Received: 3 March 2025
Accepted: 31 July 2025
First Online: 7 August 2025
Declarations
:
: The authors declare no competing interests.
: We support inclusive, diverse, and equitable conduct of research.
: Sten Madsbad.; Advisory boards: AstraZeneca; Boehringer Ingelheim; Intarcia Therapeutics; Novo Nordisk; Sanofi, Abbott Lab, Bayer, Amgen. Lecture fees: AstraZeneca; Novo Nordisk, MSD. Research Grant Recipient: Novo Nordisk; Novo Nordisk foundation, Boehringer Ingelheim. Support for attending meetings and/or travel: Novo Nordisk, Boehringer-Ingelheim, Bayer. SMA has served as PI in relation to development of drugs for treatment of Type 2 diabetes and obesity in collaboration with Novo Nordisk and Bayer. Consultant for Netdoktor. None of these commitments have had any influence on the present work.
